Adding Anti-Androgens to Late Salvage RT May Improve PCa Outcomes
Concomitant anti-androgen therapy may ameliorate the worse outcomes associated with delayed salvage radiation therapy for recurrent prostate cancer after radical surgery.
Androgen-deprivation Therapy
Apalutamide Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
The median rPFS was 24.0 months in the apalutamide arm and 16.6 months in the placebo arm.
Androgen Signaling Inhibitors Appear More Effective in Luminal Metastatic Castration-Resistant Prostate Cancer
Patients with basal tumors did not derive a significant survival benefit from androgen signaling inhibitors.
Abiraterone Added to ADT Improves Prostate Cancer Outcomes
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
Enzalutamide Shown to Slow Progression of Localized Prostate Cancer
A phase 2 exploratory study of men with low- and intermediate-risk localized prostate cancer demonstrated the oncologic benefit of enzalutamide treatment vs active surveillance.
Study: Delaying ADT for Recurrent Prostate Cancer May Not Worsen Survival
Investigators question initiation of continuous androgen deprivation therapy (ADT) for biochemically recurrent prostate cancer without metastasis.
EBRT + Androgen Suppression Improves Outcomes in Intermediate-Risk PCa
A 6-month course of androgen suppression added to external beam radiation therapy increased long-term event-free and disease-free survival compared with EBRT alone, a study found.
Prostate Cancer Mortality Risk Factors After Brachytherapy for Gleason 3+4 Identified
Addition of ADT to brachytherapy may not improve cancer-specific survival among some men with Gleason 3+4 prostate cancer.
Apalutamide Prolongs Survival in mCSPC Regardless of Disease Volume
A final analysis of the TITAN trial shows that apalutamide vs placebo added to ADT significantly lowers the risk of death and castration-resistant disease in men with metastatic castration-sensitive prostate cancer.
Intense Neoadjuvant ADT May Not Improve Post-RP Outcomes in High-Risk Prostate Cancer
Neoadjuvant androgen deprivation therapy prior to prostate cancer surgery is feasible, investigators noted.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...